Hepascore and hyaluronic acid as markers of fibrosis in liver disease of mixed aetiology

European Journal of Gastroenterology and Hepatology

Volumn 27, Issue 3, 2015, Pages 313-320

  Costelloe, Seán J ^a   Theocharidou, Eleni ^a   Tsochatzis, Emmanuel ^a   Thalassinos, Evangelos ^a   Martin, Nicholas ^a   Fede, Guiseppe ^a   Thomas, Michael ^a   Burroughs, Anthony K ^a  

^a ROYAL FREE LONDON NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Hepascore; hepatic fibrosis; hyaluronic acid; liver disease; noninvasive tests

Indexed keywords

HYALURONIC ACID; BIOLOGICAL MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HEPASCORE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER FIBROSIS; LIVER FUNCTION TEST; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STAGING; BLOOD; EVALUATION STUDY; LIVER; LIVER CIRRHOSIS; NEEDLE BIOPSY; PATHOLOGY; PROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX;

ADULT; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; FEMALE; HUMANS; HYALURONIC ACID; LIVER; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84922399690     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0000000000000267     Document Type: Article

References (21)

1. Tsochatzis EA, Bosch J, Burroughs AK. New therapeutic paradigm for patients with cirrhosis. Hepatology 2012; 56:1983-1992.
2. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995; 36:437-441.
3. Grant A, Neuberger J. Guidelines on the use of liver biopsy in clinical practice. British Society of Gastroenterology. Gut 1999; 45:IV1-IV11.
4. Adams LA, George J, Bugianesi E, Rossi E, De Boer WB, van der Poorten D, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-Alcoholic fatty liver disease. J Gastroenterol Hepatol 2011; 26:1536-1543.
5. Tsochatzis EA, Gurusamy KS, Ntaoula S, Cholongitas E, Davidson BR, Burroughs AK. Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-Analysis of diagnostic accuracy. J Hepatol 2011; 54:650-659.
6. Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, et al. ANRS HCEP 23 Fibrostar Group. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: the ANRS HCEP-23 study. J Hepatol 2012; 56:55-62.
7. Boursier J, de Ledinghen V, Zarski JP, Rousselet MC, Sturm N, Foucher J, et al. A new combination of blood test and fibroscan for accurate noninvasive diagnosis of liver fibrosis stages in chronic hepatitis C. Am J Gastroenterol 2011; 106:1255-1263.
8. Castera L. Noninvasive methods to assess liver disease in patients with hepatitis B or C. Gastroenterology 2012; 142:1293-1302.
9. Chou R, Wasson N. Blood tests to diagnose fibrosis or cirrhosis in patients with chronic hepatitis C virus infection: a systematic review. Ann Intern Med 2013; 158:807-820.
10. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005; 51:1867-1873.
11. Raftopoulos SC, George J, Bourliere M, Rossi E, de Boer WB, Jeffrey GP, et al. Comparison of noninvasive models of fibrosis in chronic hepatitis B. Hepatol Int 2011; 6:457-467.
12. Naveau S, Gaudé G, Asnacios A, Agostini H, Abella A, Barri-Ova N, et al. Diagnostic and prognostic values of noninvasive biomarkers of fibrosis in patients with alcoholic liver disease. Hepatology 2009; 49:97-105.
13. Guéchot J, Lasnier E, Sturm N, Paris A, Zarski JP. ANRS HC EP 23 Fibrostar study group. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chim Acta 2010; 411 (1-2):86-91.
14. Lichtinghagen R, Pietsch D, Bantel H, Manns MP, Brand K, Bahr MJ. The Enhanced Liver Fibrosis (ELF) score: normal values, influence factors and proposed cut-off values. J Hepatol 2013; 59:236-242.
15. El-Kamary SS, Mohamed MM, El-Raziky M, Shardell MD, Shaker OG, ElAkel WA, Esmat G. Liver fibrosis staging through a stepwise analysis of non-invasive markers (FibroSteps) in patients with chronic hepatitis C infection. Liver Int 2013; 33:982-990.
16. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988; 44:837-845.
17. Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2009; 50:36-41.
18. Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53:325-335.
19. Zhou K, Gao CF, Zhao YP, Liu HL, Zheng RD, Xian JC, et al. Simpler score of routine laboratory tests predicts liver fibrosis in patients with chronic hepatitis B. J Gastroenterol Hepatol 2010; 25:1569-1577.
20. Wu SD, Wang JY, Li L. Staging of liver fibrosis in chronic hepatitis B patients with a composite predictive model: a comparative study. World J Gastroenterol 2010; 16:501-507.
21. Adams LA, George J, Bugianesi E, Rossi E, De Boer WB, van der Poorten D, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-Alcoholic fatty liver disease. J Gastroenterol Hepatol 2011; 26:1536-1543.